慢性阻塞性肺疾病的心肺风险-降低死亡率的观点。

IF 3.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Circulation Journal Pub Date : 2025-09-25 Epub Date: 2025-06-27 DOI:10.1253/circj.CJ-24-1025
Michihiro Yoshimura, Shigeo Muro, Koichiro Kuwahara, Hisatoshi Sugiura, Koichi Fukunaga, Ryoko Sorimachi, Munehiro Seki, Toyoaki Murohara
{"title":"慢性阻塞性肺疾病的心肺风险-降低死亡率的观点。","authors":"Michihiro Yoshimura, Shigeo Muro, Koichiro Kuwahara, Hisatoshi Sugiura, Koichi Fukunaga, Ryoko Sorimachi, Munehiro Seki, Toyoaki Murohara","doi":"10.1253/circj.CJ-24-1025","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) show a relationship through the sharing of several risk factors, and the prevalence of each disease increases in an age-related manner. Therefore, clinicians are very likely to encounter patients with both diseases. Importantly, the risk of death in patients with CVD is even greater in those with coexisting COPD. Cardiopulmonary risk, defined as \"the risk of serious respiratory and/or cardiovascular events in patients with COPD,\" is a concept whereby COPD exacerbations (characterized by worsening of COPD symptoms over a short period of time) and/or CVD events may increase the risk of death due to these events in patients with COPD. Lowering cardiopulmonary risk requires appropriate treatment to prevent COPD exacerbations. Inhalation therapies can prevent COPD exacerbations and may reduce mortality rates. Research to investigate whether inhaled therapies can lower cardiopulmonary risk is ongoing. There is a need for early COPD diagnosis and timely, effective treatment that prevents COPD exacerbations while also considering cardiopulmonary risk. We propose an urgent call to action for cardiology and respirology societies to address cardiopulmonary risk and reduce COPD and CVD deaths.</p>","PeriodicalId":50691,"journal":{"name":"Circulation Journal","volume":" ","pages":"1583-1590"},"PeriodicalIF":3.7000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cardiopulmonary Risk in Chronic Obstructive Pulmonary Disease - A Perspective for Reducing Mortality.\",\"authors\":\"Michihiro Yoshimura, Shigeo Muro, Koichiro Kuwahara, Hisatoshi Sugiura, Koichi Fukunaga, Ryoko Sorimachi, Munehiro Seki, Toyoaki Murohara\",\"doi\":\"10.1253/circj.CJ-24-1025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) show a relationship through the sharing of several risk factors, and the prevalence of each disease increases in an age-related manner. Therefore, clinicians are very likely to encounter patients with both diseases. Importantly, the risk of death in patients with CVD is even greater in those with coexisting COPD. Cardiopulmonary risk, defined as \\\"the risk of serious respiratory and/or cardiovascular events in patients with COPD,\\\" is a concept whereby COPD exacerbations (characterized by worsening of COPD symptoms over a short period of time) and/or CVD events may increase the risk of death due to these events in patients with COPD. Lowering cardiopulmonary risk requires appropriate treatment to prevent COPD exacerbations. Inhalation therapies can prevent COPD exacerbations and may reduce mortality rates. Research to investigate whether inhaled therapies can lower cardiopulmonary risk is ongoing. There is a need for early COPD diagnosis and timely, effective treatment that prevents COPD exacerbations while also considering cardiopulmonary risk. We propose an urgent call to action for cardiology and respirology societies to address cardiopulmonary risk and reduce COPD and CVD deaths.</p>\",\"PeriodicalId\":50691,\"journal\":{\"name\":\"Circulation Journal\",\"volume\":\" \",\"pages\":\"1583-1590\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Circulation Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1253/circj.CJ-24-1025\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1253/circj.CJ-24-1025","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

慢性阻塞性肺疾病(COPD)和心血管疾病(CVD)通过共享几个危险因素显示出一种关系,并且每种疾病的患病率都以年龄相关的方式增加。因此,临床医生很可能会遇到患有这两种疾病的患者。重要的是,CVD患者的死亡风险比COPD患者更高。心肺风险,定义为“慢性阻塞性肺病患者发生严重呼吸和/或心血管事件的风险”,是指慢性阻塞性肺病加重(以短时间内慢性阻塞性肺病症状恶化为特征)和/或心血管事件可能增加慢性阻塞性肺病患者因这些事件而死亡的风险。降低心肺风险需要适当的治疗,以防止COPD恶化。吸入疗法可以预防COPD恶化,并可能降低死亡率。吸入疗法是否能降低心肺风险的研究正在进行中。需要对COPD进行早期诊断和及时有效的治疗,以防止COPD恶化,同时考虑到心肺风险。我们建议紧急呼吁心脏病学和呼吸学学会采取行动,以解决心肺风险并减少COPD和CVD死亡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cardiopulmonary Risk in Chronic Obstructive Pulmonary Disease - A Perspective for Reducing Mortality.

Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) show a relationship through the sharing of several risk factors, and the prevalence of each disease increases in an age-related manner. Therefore, clinicians are very likely to encounter patients with both diseases. Importantly, the risk of death in patients with CVD is even greater in those with coexisting COPD. Cardiopulmonary risk, defined as "the risk of serious respiratory and/or cardiovascular events in patients with COPD," is a concept whereby COPD exacerbations (characterized by worsening of COPD symptoms over a short period of time) and/or CVD events may increase the risk of death due to these events in patients with COPD. Lowering cardiopulmonary risk requires appropriate treatment to prevent COPD exacerbations. Inhalation therapies can prevent COPD exacerbations and may reduce mortality rates. Research to investigate whether inhaled therapies can lower cardiopulmonary risk is ongoing. There is a need for early COPD diagnosis and timely, effective treatment that prevents COPD exacerbations while also considering cardiopulmonary risk. We propose an urgent call to action for cardiology and respirology societies to address cardiopulmonary risk and reduce COPD and CVD deaths.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Circulation Journal
Circulation Journal 医学-心血管系统
CiteScore
5.80
自引率
12.10%
发文量
471
审稿时长
1.6 months
期刊介绍: Circulation publishes original research manuscripts, review articles, and other content related to cardiovascular health and disease, including observational studies, clinical trials, epidemiology, health services and outcomes studies, and advances in basic and translational research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信